What is the standard S-23 dosing protocol?

See the fact-checked Verified Dosing shown at the top of this page (verified against the FDA label / published trials); always confirm with a licensed provider.

How do you take S-23?

S-23 is an oral compound supplied as capsules. No reconstitution is required. Swallow the capsule with water at the same time each day.

What are the storage requirements for S-23?

Store capsules at room temperature in a cool, dry place. Keep tightly sealed, away from moisture and direct light.

S-23 — Research Literature Summary

✓ Verified dosing (fact-checked against FDA labels / published trials): No validated human dose exists. S-23 has never been studied in humans in a clinical trial and has no FDA label. The only dosing in the scientific literature is preclinical: oral 0.1-1.0 mg/kg/day in rats (often with low-dose estradiol). The site's '10 mg, morning, 7 capsules/week (oral)' figure is vendor-templated and not supported by… This supersedes any conflicting figures shown elsewhere on this page; confirm with a licensed provider.

Class: SARM • Page type: research-literature reference • Updated 2026-04-23

Regulatory notice — research reference only

S-23 is a research-chemical SARM with no published human clinical trials. It has not been approved for human use by any regulatory authority and is not eligible for sale for human consumption in the United States. This page summarizes preclinical literature only.

Published research summary

S-23 is a nonsteroidal SARM characterized primarily in rodent studies from the Dalton lab and collaborators.
Preclinical rodent data describe dose-dependent increases in lean mass and bone density, as well as reversible suppression of spermatogenesis at higher doses (investigated as a potential male contraceptive concept).
No peer-reviewed human pharmacokinetics, efficacy, or safety studies of S-23 have been published.
S-23 is prohibited at all times on the WADA Prohibited List (S1.2) by structural class.

Why this page does not publish a consumer “cycle” schedule

There is no peer-reviewed human research to ground dose or duration guidance. Any consumer protocol would be extrapolation from rodent data only.

Peer-reviewed citations

Jones A, et al. Endocrinology 2009;150(1):385-395 (preclinical SARM characterization, Dalton lab).

Consulting a healthcare provider: This page is a reference for published research. If you are considering any health decision, consult a licensed healthcare provider. Path to Peptides does not provide medical advice.

⚠ Before any use: human safety data is limited or absent for many of these compounds. Consult a licensed healthcare provider first — especially if you are pregnant or nursing, have a medical condition, or take other medications.